AngioDynamics 'Exceptionally Well-Positioned' For 2026, CEO Says: But Tariffs Still Sting
1. ANGO's Q4 loss was 3 cents per share, beating expectations. 2. Sales reached $80.2 million, exceeding consensus estimates by 8.7%. 3. Med Tech sales rose 22% year-over-year, primarily driven by Auryon. 4. 2026 revenue guidance is $305-$310 million, slightly exceeding consensus. 5. Stock increased 5.3% to $10.14 following positive earnings report.